Occidental Asset Management LLC Acquires 289 Shares of Johnson & Johnson (NYSE:JNJ)

Occidental Asset Management LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 8.5% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,705 shares of the company’s stock after buying an additional 289 shares during the period. Occidental Asset Management LLC’s holdings in Johnson & Johnson were worth $600,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the stock. Richardson Financial Services Inc. acquired a new position in Johnson & Johnson during the 4th quarter worth approximately $54,000. PVG Asset Management Corp grew its position in Johnson & Johnson by 28.8% in the 4th quarter. PVG Asset Management Corp now owns 3,899 shares of the company’s stock valued at $611,000 after purchasing an additional 872 shares during the period. Sivia Capital Partners LLC bought a new stake in Johnson & Johnson during the 4th quarter valued at $592,000. Golden Road Advisors LLC acquired a new position in Johnson & Johnson during the fourth quarter worth $238,000. Finally, Ables Iannone Moore & Associates Inc. bought a new position in shares of Johnson & Johnson in the fourth quarter valued at $2,300,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.1 %

Johnson & Johnson stock opened at $161.60 on Tuesday. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $388.92 billion, a P/E ratio of 10.07, a P/E/G ratio of 2.65 and a beta of 0.52. The firm has a 50 day moving average price of $162.60 and a 200-day moving average price of $154.48. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating the consensus estimate of $2.71 by $0.11. The business had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. Johnson & Johnson’s revenue was up 4.3% compared to the same quarter last year. During the same period in the prior year, the company earned $2.80 earnings per share. As a group, equities analysts predict that Johnson & Johnson will post 10 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.07%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

JNJ has been the topic of several recent research reports. Daiwa Capital Markets cut shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Thursday, October 10th. TD Cowen lowered their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. The Goldman Sachs Group reduced their target price on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. Finally, Sanford C. Bernstein raised their price target on shares of Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Six equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $174.31.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.